Background: Metastatic pancreatic and periampullary adenocarcinoma is associated with a poor prognosis, with a life expectancy of less than one year at diagnosis, a 5-year survival rate of only 1-2%, and a median survival of 3 to 6 months. In the Philippines, pancreatic cancer is the 14th most common cancer and the 8th leading cause of cancer-related death, with over 153,000 cases and 92,600 deaths reported in 2020. Current literature suggests that in carefully selected patients, synchronous resection of primary pancreatic and periampullary adenocarcinoma with liver metastases can yield favorable surgical outcomes with low morbidity and mortality. However, survival outcome data for such cases within the Philippine population remain limited. Objective: To evaluate survival rates in patients with pancreatic and periampullary adenocarcinoma with oligometastasis who underwent pancreatic resection and metastasectomy at the Philippine General Hospital from 2011 to 2021. Methods: A retrospective cohort study was conducted using data collected from the Department of Surgery’s electronic medical records, cross-referenced with the Philippine Statistics Authority’s death registry. Inclusion criteria included patients aged 19 and above with histologically confirmed pancreatic and periampullary adenocarcinoma with three or fewer metastases. Descriptive statistics were calculated, and Kaplan-Meier survival analysis was used to determine overall survival rates. Results: Of the patients reviewed, 75% were female, with a median age of diagnosis of 60 years. Tumor locations included the pancreatic head (50% of cases), ampullary region (37.5%), and pancreatic body/tail (12.5%). The 1-year survival rate was 62.5%, the 2-year survival rate was 25%, and the median overall survival was 17.3 months, with a range from 7 to 28.8 months. Conclusion The findings suggest that synchronous resection of primary tumors and metastases may offer survival benefits for selected patients with metastatic pancreatic and periampullary cancers. However, further prospective clinical trials are necessary to confirm the potential survival advantage of this approach in a broader population.
metastasectomy

RATIONALE: The liver is the most common site of metastasis from colorectal cancer. Curative intent liver metastasectomy has shown improvement in overall survival. This manuscript will present the long-term oncologic outcomes of hepatic metastasectomy for colorectal cancer with resectable liver metastasis. METHODS: Data of patients with resectable liver metastases from colorectal cancer who underwent hepatic resection at the Philippine General Hospital over a 10-year period was reviewed. The primary outcome investigated was overall survival. RESULTS: Thirty patients were included in the study. The median overall survival was 20 months, with a 2-year and 5-year overall survival rate of 40% and 6.67% respectively. Eleven (36.67%) patients had disease recurrence, with a median disease-free survival of 16 months. A significant difference in survival was seen between patients with synchronous and metachronous liver metastasis (20.38 and 36.78 months respectively, p=0.0393) and in patients given adjuvant chemotherapy at any time in relation to the occurrence of the liver metastases versus patients who did not receive any adjuvant treatment (34.08 and 18.59 months respectively, p=0.0349). Trends towards improved overall survival were seen in patients 50 years old or less (36.86 versus 21.78 months, p=0.0837) and in patients with a clinical risk score of 2 or less (29.65 versus 19.62 months, p=0.1823), which may show significance in a higher powered study CONCLUSION Improved overall survival was observed among patients with colorectal liver metastases undergoing hepatic metastasectomy compared to no liver resection.
Metastasectomy ; Philippines

PURPOSE: We performed a comparative analysis of the clinicopathologic features and oncologic outcomes of colorectal cancer patients with metachronous versus synchronous metastasis, according to the prognostic factors. METHODS: Ninety-three patients who underwent curative resection for distant metastatic colorectal cancer were included in the study between December 2001 and December 2011. We assessed recurrence-free survival and overall survival in patients with distant metastasis who underwent curative surgery. RESULTS: The most common site of distant metastasis was lung alone (n = 19, 51.4%) in patients with metachronous metastasis, while liver alone was most common in those with synchronous metastasis (n = 40, 71.4%). Overall survival rate was significantly different between patients with synchronous metastasis and metachronous metastasis (34.0% vs. 53.7%; P = 0.013). Incomplete resection of the metastatic lesion was significantly related to poor overall survival in both, patients with synchronous metastasis, and metachronous metastasis. CONCLUSION: Our study indicates that patients developing distant metastasis after initial treatment show a different metastatic pattern and better oncologic outcomes, as compared to those presenting with distant metastasis. Resection with tumor free margins significantly improves survival in patients with metachronous as well as synchronous metastasis.
Colorectal Neoplasms* ; Humans ; Liver ; Lung ; Metastasectomy* ; Neoplasm Metastasis* ; Survival Rate

The lung is a common site for metastasis of malignant tumors from other organs. The metastatic cascade is a complex process that involves a series of events. Tumors can spread to the lung through hematogenous or lymphangitic routes. In the absence of extrathoracic metastasis, complete resection is associated with increased survival, regardless of histology. With appropriate patient selection, life expectancy is often improved with pulmonary metastasectomy. Stereotactic body radiation therapy (SBRT) and radiofrequency ablation (RFA) are 2 approaches that have been increasingly reported for pulmonary tumors. Although these new therapies have yet to match the long-term success rates of surgical therapy, the techniques demonstrate good results in treating high-risk surgical candidates with metastatic lesions to the lungs that would otherwise be considered with resection. This review will focus on the role of local therapy in oligometastasis that arise in the lung.
Life Expectancy ; Lung ; Metastasectomy ; Neoplasm Metastasis ; Patient Selection

PURPOSE: To evaluate the effect of pelvic radiotherapy (RT) in patients with stage IV rectal cancer treated with resection of primary tumor with or without metastasectomy. MATERIALS AND METHODS: Medical records of 112 patients with stage IV rectal cancer treated with resection of primary tumor between 1990 and 2011 were retrospectively reviewed. Fifty-nine patients received synchronous or staged metastasectomy whereas fifty-three patients did not. Twenty-six patients received pelvic radiotherapy. RESULTS: Median overall survival (OS), locoregional recurrence-free survival (LRFS), and progression-free survival (PFS) of all patients was 27, 70, and 11 months, respectively. Pathologic T (pT), N (pN) classification and complete metastasectomy were statistically significant factors in OS (p = 0.040, 0.020, and 0.002, respectively). RT did not improve OS or LRFS. There were no significant factors in LRFS. pT and pN classification were also significant prognostic factors in PFS (p = 0.010 and p = 0.033, respectively). In the subgroup analysis, RT improved LRFS in patients with pT4 disease (p = 0.026). The locoregional failure rate of the RT group and the non-RT group were 23.1% and 33.7%, showing no difference in the failure pattern of both groups (p = 0.260). CONCLUSION: Postoperative pelvic RT did not improve LRFS of all metastatic rectal cancer patients; however, it can be recommended to patients with pT4 disease. A complete resection of metastatic masses should be performed if possible.
Disease-Free Survival ; Humans ; Medical Records ; Metastasectomy ; Neoplasm Metastasis ; Neoplasm Recurrence, Local ; Rectal Neoplasms ; Retrospective Studies

PURPOSE: We reviewed clinical feature and survival rates of metastatic renal cell carcinoma(RCCa) and analyzed the prognostic factors and surgical outcomes in patients who underwent surgical resection of metastatic RCCa. MATERIALS AND METHODS: Among 287 patients who underwent radical nephrectomy for RCCa from January 1990 to June 1997, 65 patients had metastatic disease. In 31 patients, metastatic lesions were surgically removed. Survival rates were analyzed according to various prognostic factors(the completeness of metastasectomy, synchronicity or metachronicity of metastasis, interval to metastasis after radical nephrectomy, Fuhrman`s grade of metastatic lesions and interval to the development of a new metastatic lesion after metastasectomy) RESULTS: The metastasectomy was complete in 18 and incomplete in 13, and 3-year survival rates were 59% and 8%, respectively(p=0.0013). In the group of patients who underwent complete resection of metastatic lesion, time to recurrence was significantly influential on survival with 3 year survival rate of 100% and 15% for those whose disease recurred after and before 12 months, respectively(p=0.001). For those who underwent curative resection of the metastatic lesion, synchronicity or metachronicity of metastasis, time to metastasis and Fuhrman`s grade did not influence survival after complete resection (p=0.675, p=0.607 and p=0.074). CONCLUSIONS: Aggressive surgical treatment should be considered in selected cases in whom complete resection of the metastatic lesion is feasible for the purpose of long term survival. If no newly developed lesion is found within 1 year after operation, favorable prognosis could be expected.
Carcinoma, Renal Cell* ; Humans ; Metastasectomy* ; Neoplasm Metastasis ; Nephrectomy ; Prognosis ; Recurrence ; Survival Rate

PURPOSE: Controversies regarding preoperative versus postoperative chemotherapy for patients having hepatic metastases of colorectal primary made us elucidate the safety of chemotherapy. By examining the histopathologic changes in the liver following preoperative chemotherapy and analyzing the relation between surgical outcomes and preoperative chemotherapy, we were able to answer whether preoperative chemotherapy is safe. METHODS: We analyzed 38 patients who underwent chemotherapy before resection of hepatic metastasis from colorectal primary, retrospectively. Types of chemotherapy regimen were FL (5-FU+leucovorin), FOLFOX4 (oxaliplatin+5-FU+leucovorin), and FOLFIRI (irinotecan+5-FU+leucovorin). Results of liver function tests were compared before and after preoperative chemotherapy. One pathologist reviewed the degree of hepatic injury from resected specimens. Associations between the histological findings of hepatic injury and surgical outcomes and chemotherapeutic agents were examined. RESULTS: Histopathologic analysis revealed severe liver injury was present in 12 patients (31.6%). In further detail, moderate to severe sinusoidal dilatation was found in 3 patients (25%), steatosis of more than 30% was identified in 9 patients (75%), and steatohepatitis Kleiner score of > or =4 in 5 patients (41.7%). Preoperative chemotherapy did not affect the biochemical profiles of liver function. The overall perioperative complication rate was 5.3% (n=2). There was no difference in postoperative morbidity or mortality from reported results following hepatectomy. CONCLUSION: We found preoperative chemotherapy definitely induced histopathologic changes of hepatotoxicities. Even so, preoperative chemotherapy did not increase morbidity or mortality after hepatic metastasectomy. Preoperative chemotherapy seems to be safe in performing curative hepatic resection for the metastases.
Colonic Neoplasms ; Dilatation ; Fatty Liver ; Humans ; Liver ; Liver Function Tests ; Metastasectomy ; Neoplasm Metastasis ; Retrospective Studies

Recurrence of hepatocellular carcinoma (HCC) after hepatic resection is quite common. Peritoneal recurrence has been considered incurable status and related to poor prognosis. Although peritoneal metastasectomy is a therapeutic option for some selected patients with a few peritoneal metastasis, the indication and therapeutic effect has not been clear. We report a case of a 61-year-old man achieving complete remission of recurrent peritoneal metastasis after repeated surgical resection by a multidisciplinary approach. Peritoneal metastasectomy might be a therapeutic option for selected patients with localized oligonodular peritoneal metastasis.
Carcinoma, Hepatocellular* ; Hepatectomy* ; Humans ; Metastasectomy ; Middle Aged ; Neoplasm Metastasis* ; Prognosis ; Recurrence

This is a report of successful management for pulmonary metastasis following chemotherapy in patient with testicular germ cell tumor. Postchemotherapy PET-CT was not uptake FDG in metastatic lesion. Pulmonary metastasectomy was performed, which is important to manage a residual postchemotherapy lung mass in testicular germ cell tumor for histological correlation with primary testicular lesion to select the patients who require subsequent chemotherapy. Our patient was well 6 months after operation, not carried out chemotherapy because of no viable tumor.
Germ Cells ; Humans ; Lung ; Metastasectomy ; Neoplasm Metastasis ; Neoplasms, Germ Cell and Embryonal ; Testicular Neoplasms ; Testis

Benign metastasizing leiomyoma (BML) is a rare entity, characterized by the occurrence of multiple smooth muscle nodules in the lung with histologically benign leiomyoma. Both the uterine and pulmonary tumors have been found to express estrogen and progesterone receptors, which suggest that the pulmonary lesions represented metastases from leiomyoma. We experienced a 41-year-old female patient with BML and report here with the literature review.
Adult ; Estrogens ; Female ; Humans ; Leiomyoma* ; Lung Neoplasms ; Lung* ; Metastasectomy ; Muscle, Smooth ; Neoplasm Metastasis ; Receptors, Progesterone